Desvenlafaxine Succinate: A Newer Antidepressant for the Treatment of Depression and Somatic Symptoms

References

• . Kessler RC, Merikangas KR, Wang PS. Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century. Annu Rev Clin Psychol. 2007;3:137–158
   PubMed Web of Science ®Google Scholar
• . Kessler RC, Berglund P, Demler O,; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095–3105
   PubMed Web of Science ®Google Scholar
• . Alonso J, Angermeyer MC, Bernert S,; ESEMeD/MHEDEA 2000 Investigators, European Study of the Epidemiology of Mental Disorders (ESEMeD) Project. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;(420):21–27
   Google Scholar
• . Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008;358(1):55–68
   PubMed Web of Science ®Google Scholar
• . Cipriani A, Furukawa TA, Salanti G,. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746–758
   PubMed Web of Science ®Google Scholar
• . Trivedi MH, Rush AJ, Wisniewski SR,; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40
   PubMed Web of Science ®Google Scholar
• . Rush AJ, Trivedi MH, Wisniewski SR,. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917
   PubMed Web of Science ®Google Scholar
• . Deecher DC, Beyer CE, Johnston G,. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006;318(2):657–665
   PubMed Web of Science ®Google Scholar
• . Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2007;22(6):338–347
   PubMed Web of Science ®Google Scholar
• . Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry. 2007;68(11):1663–1672
   PubMed Web of Science ®Google Scholar
• . Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin. 2008;24(7):1877–1890
   PubMed Web of Science ®Google Scholar
• . Lieberman DZ, Montgomery SA, Tourian KA,. A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol. 2008;23(4):188–197
   PubMed Web of Science ®Google Scholar
• . DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007;68(5):677–688
   PubMed Web of Science ®Google Scholar
• . Wyrwich KW, Spratt DI, Gass M, Yu H, Bobula JD. Identifying meaningful differences in vasomotor symptoms among menopausal women. Menopause. 2008;15(4 pt 1):698–705
   PubMedGoogle Scholar
• . Speroff L, Gass M, Constantine G, Olivier S; Study 315 Investigators. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol. 2008;111(1):77–87
   PubMedGoogle Scholar
• . Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG,. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001;25(6):871–880
   PubMed Web of Science ®Google Scholar
• . Kamath J, Handratta V. Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008;8(12):1787–1797
   PubMedGoogle Scholar
• . Mason JN, Deecher DC, Richmond RL,. Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007;323(2):720–729
   PubMedGoogle Scholar
• . Preskorn SH, Nichols AI, Paul J, Patroneva AL, Helzner EC, Guico-Pabia CJ. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. J Psychiatr Pract. 2008;14(6):368–378
   PubMed Web of Science ®Google Scholar
• . Preskorn S, Patroneva A, Silman H,. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol. 2009;29(1):39–43
   PubMed Web of Science ®Google Scholar
• . Nichols AI, Fatato P, Shenouda M,. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol. 2009;49(2):219–228
   PubMedGoogle Scholar
• . Patroneva A, Connolly SM, Fatato P,. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos. 2008;36(12):2484–2491
   PubMed Web of Science ®Google Scholar
• . Boyer P, Montgomery S, Lepola U,. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23(5):243–253
   PubMed Web of Science ®Google Scholar
• . Feiger AD, Tourian KA, Rosas GR, Padmanabhan SK. A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. CNS Spectr. 2009;14(1):41–50
   PubMed Web of Science ®Google Scholar
• . Khan A, Upton GV, Rudolph RL, Entsuah R, Leventer SM. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group. J Clin Psychopharmacol. 1998;18(1):19–25
   PubMedGoogle Scholar
• . Thase ME, Kornstein SG, Germain JM, Jiang Q, Guico-Pabia C, Ninan PT. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr. 2009;14(3):144–154
   PubMed Web of Science ®Google Scholar
• . Clayton AH, Kornstein SG, Rosas G, Guico-Pabia C, Tourian KA. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr. 2009;14(4):183–195
   PubMed Web of Science ®Google Scholar
• . Cookson J, Gilaberte I, Desaiah D, Kajdasz DK. Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat. Int Clin Psychopharmacol. 2006;21(5):267–273
   PubMedGoogle Scholar
• . Berendsen HH. The role of serotonin in hot flushes. Maturitas. 2000;36(3):155–164
   PubMed Web of Science ®Google Scholar
• . Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol. 2005;105(1):161–166
   PubMed Web of Science ®Google Scholar
• . Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA. 2003;289(21):2827–2834
   PubMed Web of Science ®Google Scholar
• . Deecher DC, Alfinito PD, Leventhal L,. Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent models. Endocrinology. 2007;148(3):1376–1383
   PubMedGoogle Scholar
• . Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S; Study 319 Investigators. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol. 2009;200(3):238.e231–238.e210
   Google Scholar
• . Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol. 2009;200(2):172. e171–110
   PubMedGoogle Scholar
• . Ossipov MH, Porreca F. Challenges in the development of novel treatment strategies for neuropathic pain. Neuro Rx. 2005;2(4):650–661
   Google Scholar
• . Arnold LM, Lu Y, Crofford LJ,. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50(9):2974–2984
   PubMed Web of Science ®Google Scholar
• . Arnold LM, Rosen A, Pritchett YL,. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119(1–3):5–15
   PubMed Web of Science ®Google Scholar
• . Gendreau RM, Thorn MD, Gendreau JF,. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005;32(10):1975–1985
   PubMed Web of Science ®Google Scholar
• . Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol. 2004;19( suppl 1):S27–S35
   PubMed Web of Science ®Google Scholar
• . Han C, Pae CU, Lee BH,. Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder: a 12-week prospective, open-label, randomized, parallel-group trial. Clin Drug Investig. 2008;28(4):251–261
   PubMedGoogle Scholar
• . Kroenke K, Messina N 3rd, Benattia I, Graepel J, Musgnung J. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. J Clin Psychiatry. 2006;67(1):72–80
   PubMedGoogle Scholar
• . Pae CU, Lim HK, Ajwani N, Lee C, Patkar AA. Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder. Expert Rev Neurother. 2007;7(6):603–615
   PubMedGoogle Scholar